Collaboration and License Agreements - Additional Information (Details)			1 Months Ended		12 Months Ended
	Oct. 26, 2021 USD ($)	May 05, 2021 CrisprCas9	Aug. 31, 2016 USD ($) shares	Aug. 31, 2016 SGD ($) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development costs					$ 63,412,000	$ 36,220,000
Research Collaboration Agreement | Development and Regulatory Approval Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential future payments					totaling less than mid-twenty million dollars
Amount paid under the agreement					$ 0
Amounts owed under the agreement					0
Receivable under research cost sharing provision					1,100,000
MaxCyte License Agreement | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone payments	$ 10,000,000
Net sales milestone payments	61,900,000
Annual research license fees and Commercialization license fees	100,000
MaxCyte License Agreement | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone payments	13,000,000
Net sales milestone payments	116,800,000
Annual research license fees and Commercialization license fees	$ 300,000
NK Cell Products | Research Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of non-exclusive rights to gene editing targets | CrisprCas9		5
NUS and St. Jude | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment			$ 31,800	$ 42,750
Upfront payment, shares issued | shares			250,000	250,000
Fair value of common stock issued			$ 2,500
Annual license maintenance fee				$ 25,000
Potential milestone payments				$ 5,000,000
Percentage of licensors royalties			2.50%	2.50%
Milestone payment					100,000
NUS and St. Jude | License Agreement | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of sublicensing income			7.50%	7.50%
NUS and St. Jude | License Agreement | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of sublicensing income			20.00%	20.00%
License agreement term			120 months	120 months
NUS and St. Jude | License Maintenance Fees | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development costs					$ 37,000	$ 37,000
NUS and St. Jude | After Year Two of the Agreement | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Annual license maintenance fee				$ 50,000